DRUG DELIVERY PLATFORMS

Kinesyx

Kinesyx Logo

TARGETTED DRUG DELIVERY EXCIPIENTS

Our patent protected Kinesyx® excipient is purposely designed for coating performance and drug delivery control using a straightforward, reproducible manufacturing process. The current focus of the Kinesyx® technology is on a Sirolimus Drug Coated Balloon (DCB) for coronary and peripheral vascular disease indications.

structure

 

Kinesyx® Excipient

  • Molecular structure imparts coating integrity
  • Amphiphilic properties
  • Biocompatible and hemocompatible
  • Clinically proven safety with >800,000 patients in vascular access indications

Crystalline Sirolimus

  • Optimized tissue retention
  • Microparticle target size 5-10 µm 

With our Sirolimus DCB coating, we have demonstrated high drug retention at 28 days in porcine coronary and peripheral models. Low particulate generation and low loss of drug during transit to the target site support safety and potential for controlled target lesion drug delivery.

Porcine graph

Particulate graph

ADVANTAGES

TECHNOLOGY ADVANTAGES
  • Sustained Drug Delivery
  • Low Particulate Generation
  • Simple Coating Process
  • Multiple Site Delivery
  • Clinically Proven Excipient

PRODUCT APPLICATION

DRUG COATED BALLOON
  • Efficiently delivers drug to target
  • Minimizes embolic risk
  • Straightforward, reproducible manufacturing
  • Operator procedural flexibility
  • Excipient used for blood-contacting applications in > 800,000 patients
Powered by Innovasium